Equity investment in ITB-Med (SE) by a syndicate led by Pablo Legorreta, the founder and CEO of Royalty Pharma — USD 67 million

Carnegie acted as adviser to ITB-Med in connection with the equity investment in ITB-Med by a syndicate led by Pablo Legorreta, the founder and CEO of Royalty Pharma. ITB-Med is a biopharmaceutical company focusing on the development of specific immunomodulatory biologics for use primarily in organ and stem cell transplantation. April 2018.